Home
/

What is a Cholesterol/HDL Ratio Blood Test?

REVIEWED BY
Bill Maish, MD
Clinical Content Consultant
Published
May 30, 2026
Last updated
May 30, 2026
Quick answer:

The Cholesterol/HDL Ratio compares total cholesterol to HDL cholesterol, condensing the balance between cholesterol delivery to tissues and HDL-mediated reverse transport into a single cardiovascular risk indicator. Values in the low 3s are generally favorable, around 4–5 is average, and higher ratios indicate increasing atherogenic exposure. Tracking this ratio over time may help support assessment of whether lifestyle changes or medications are shifting lipid balance toward lower cardiovascular risk.

Read more →
Table of contents

The Tug-of-War Between Cholesterol Delivery and HDL Cleanup

The cholesterol/HDL ratio blood test reports a calculated indicator from a standard lipid panel. It compares the amount of cholesterol circulating in all particles combined (total cholesterol) with the portion carried by the "scavenger" particles that help ferry cholesterol away from tissues (HDL cholesterol). Cholesterol itself is a waxy, fat-like substance made in the liver and absorbed from food (cholesterol), and it cannot travel alone in the bloodstream. It rides inside protein-coated carriers called lipoproteins—delivery-focused particles (apoB-containing lipoproteins such as LDL, VLDL, IDL, and Lp(a)) and cleanup-focused particles (HDL).

Biologically, this ratio reflects the tug-of-war between cholesterol delivery to cells and vessel walls (apoB lipoproteins) and cholesterol retrieval back to the liver for disposal or reuse (reverse cholesterol transport via HDL). By condensing that balance into a single number, it offers a snapshot of how cholesterol traffic is partitioned at a given time. It does not measure cholesterol's function directly; rather, it indicates the distribution of cholesterol among carriers that tend to deposit it versus carriers that remove it. That distribution is central to how cholesterol is handled throughout the body and within arteries.

A Compact Signal of Vascular Well-Being

The cholesterol/HDL ratio captures the balance between cholesterol that tends to deposit in artery walls and HDL, which helps carry cholesterol away. It is a compact signal of vascular well‑being across the heart, brain, kidneys, and peripheral circulation, reflecting both lipid burden and the efficiency of reverse cholesterol transport.

Big picture: this ratio integrates with LDL, non‑HDL, triglycerides, apolipoprotein B, glucose–insulin balance, and inflammation. Over time, higher ratios track with greater risk of atherosclerotic cardiovascular disease and stroke, while lower ratios align with more resilient vasculature and healthier aging.

Where Your Cholesterol/HDL Ratio Falls

Most labs consider lower ratios better. Values in the low 3s are generally favorable, around 4–5 is average, and higher than that suggests increasing atherogenic exposure. Within reference ranges sits toward the lower end because fewer damaging particles relative to HDL means calmer endothelium, less plaque growth, and better vessel function.

When the ratio is low, HDL is relatively strong compared with total cholesterol. Physiology tilts toward clearance of cholesterol from tissues, improved nitric oxide signaling, and quieter vascular inflammation. People usually feel nothing—this is a protective state. Women, especially before menopause, often have lower ratios due to higher HDL. In pregnancy, lipid levels rise and the ratio may transiently climb. Rarely, an extremely low ratio driven by unusually high HDL may not confer extra protection if HDL is dysfunctional. When very low from suppressed total cholesterol, it can accompany too much thyroid hormone (hyperthyroidism), malabsorption, chronic liver disease, undernutrition, or systemic inflammation.

Being in range suggests balanced cholesterol trafficking, adequate HDL function, and stable lipoprotein turnover that supports vessel health, steroid hormone production, and immune cell membranes. For risk prediction, optimal tends to sit toward the lower end of the laboratory range, indicating fewer apoB particles relative to HDL.

When the ratio is high, either atherogenic lipoproteins are elevated or HDL is low. This fosters endothelial injury, foam cell formation, and plaque buildup that can manifest later as chest pressure with exertion, leg pain when walking, transient neurologic symptoms, or erectile dysfunction in men. Men tend to run higher ratios than women; ratios often rise after menopause. In children and teens, a high ratio can flag familial lipid disorders even without symptoms. This pattern is common with insulin resistance, central adiposity, too little thyroid hormone (hypothyroidism), nephrotic syndrome, and chronic inflammatory states.

What Can Distort the Cholesterol/HDL Ratio

Notes: Interpret alongside LDL-C, non-HDL-C, triglycerides, apoB, and clinical context. Non-fasting sampling and acute illness can lower HDL and inflate the ratio. Medications and hormones (statins, estrogen, androgens, beta-blockers, diuretics) and genetic conditions (familial hypercholesterolemia, CETP variants) influence results; minor lab-to-lab variability exists.

FAQs

It calculates total cholesterol divided by HDL cholesterol from a standard lipid panel to summarize the balance between atherogenic cholesterol and protective HDL.

It helps gauge cardiovascular risk more clearly than total cholesterol alone, highlights patterns linked to insulin resistance and metabolic syndrome, and shows how lifestyle changes affect lipid balance.

Test periodically to establish a baseline and track trends over time, especially when adjusting diet, activity, weight, medications, or during life-stage changes.

Diet, physical activity, body composition, sleep, stress, tobacco exposure, medications, and hormonal shifts (including menopause and androgens) can influence results.

The ratio is reliable in non-fasting states. If triglycerides or other fasting-sensitive markers are included, fasting may be requested for consistency.

Superpower currently offers at-home blood testing in the following states: Alabama, Arizona, California, Colorado, Connecticut, Delaware, District of Columbia, Florida, Georgia, Idaho, Illinois, Indiana, Kansas, Maine, Maryland, Massachusetts, Michigan, Minnesota, Missouri, Montana, Nebraska, Nevada, New Hampshire, New Jersey, New Mexico, New York, North Carolina, Ohio, Oklahoma, Oregon, Pennsylvania, South Carolina, Tennessee, Texas, Utah, Vermont, Virginia, Washington, West Virginia, and Wisconsin.

We’re actively expanding nationwide, with new states being added regularly. If your state isn’t listed yet, stay tuned.

References

  1. Millán, J., Pintó, X., Muñoz, A., Zúñiga, M., Rubiés-Prat, J., Pallardo, L. F., Masana, L., Mangas, A., Hernández-Mijares, A., González-Santos, P., Ascaso, J. F., & Pedro-Botet, J. (2009). Lipoprotein ratios: Physiological significance and clinical usefulness in cardiovascular prevention. Vascular Health and Risk Management, 5, 757-765. https://pubmed.ncbi.nlm.nih.gov/19774217/
  2. Emerging Risk Factors Collaboration. (2009). Major lipids, apolipoproteins, and risk of vascular disease. JAMA, 302(18), 1993-2000. https://doi.org/10.1001/jama.2009.1619
  3. Grundy, S. M., Stone, N. J., Bailey, A. L., Beam, C., Birtcher, K. K., Blumenthal, R. S., Braun, L. T., de Ferranti, S., Faiella-Tommasino, J., Forman, D. E., Goldberg, R., Heidenreich, P. A., Hlatky, M. A., Jones, D. W., Lloyd-Jones, D., Lopez-Pajares, N., Ndumele, C. E., Orringer, C. E., Peralta, C. A., ... Yeboah, J. (2019). 2018 AHA/ACC/AACVPR/AAPA/ABC/ACPM/ADA/AGS/APhA/ASPC/NLA/PCNA guideline on the management of blood cholesterol. Circulation, 139(25), e1082-e1143. https://doi.org/10.1161/CIR.0000000000000625
  4. Prospective Studies Collaboration. (2007). Blood cholesterol and vascular mortality by age, sex, and blood pressure: A meta-analysis of individual data from 61 prospective studies with 55,000 vascular deaths. Lancet, 370(9602), 1829-1839. https://doi.org/10.1016/S0140-6736(07)61778-4
  5. Sniderman, A. D., Thanassoulis, G., Glavinovic, T., Navar, A. M., Pencina, M., Catapano, A., & Ference, B. A. (2019). Apolipoprotein B particles and cardiovascular disease: A narrative review. JAMA Cardiology, 4(12), 1287-1295. https://doi.org/10.1001/jamacardio.2019.3780

Built by the world’s top doctors and scientists

Dr Anant Vinjamoori, MD

Chief Longevity Officer, Superpower

Board-certified longevity physician. Previously product leader at Virta Health & CMO at Modern Age. Featured in  WSJ, Forbes, and Fortune.

Learn more

Dr Leigh Erin Connealy, MD

Clinician & Founder of The Centre for New Medicine

Leads the largest integrative medical clinic in North America. A pioneer in integrative oncology.

Learn more

Dr Robert Lufkin

UCLA Medical Professor, NYT Bestselling Author

A leading voice on metabolic health and longevity as shown in The Today Show, USA Today and FOX.

Learn more

Dr Abe Malkin

Founder & Medical Director of Concierge MD

Leads a nationwide medical practice, and Drip Hydration, a mobile IV therapeutics company

Learn more
Membership slide 1
Membership slide 1
Membership slide 2
Membership slide 3
1 / 3

Your membership starts here

Annual 100+ biomarker panel

Data dashboard and digital twin

Upload past labs and connect wearables

Personalized health protocol

24/7 care team access

AI companion for all health questions

Marketplace with additional solutions

$199

/year*

Billed annually

HSA/ FSA eligible
Cancel anytime
Results in a week

* Pricing may vary for members in New York and New Jersey